
- <Centre d'Information et de documentation du CRA Rhône-Alpes
- CRA
- Informations pratiques
-
Adresse
Centre d'information et de documentation
Horaires
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexLundi au Vendredi
Contact
9h00-12h00 13h30-16h00Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Adresse
Détail de l'auteur
Auteur Geir BJØRKLUND |
Documents disponibles écrits par cet auteur (2)



Awareness and risk factors of autism spectrum disorder in an Egyptian population / Nagwa ABDEL MEGUID in Research in Autism Spectrum Disorders, 84 (June 2021)
![]()
[article]
Titre : Awareness and risk factors of autism spectrum disorder in an Egyptian population Type de document : Texte imprimé et/ou numérique Auteurs : Nagwa ABDEL MEGUID, Auteur ; Neveen Hassan NASHAAT, Auteur ; Amal ELSAEID, Auteur ; Massimiliano PEANA, Auteur ; Ahmed ELNAHRY, Auteur ; Geir BJØRKLUND, Auteur Article en page(s) : 101781 Langues : Anglais (eng) Mots-clés : Autism Awareness Referral situations Risk factors Index. décimale : PER Périodiques Résumé : Background The aim of the present study was to determine the type and percentage of referral situations, risk factors, associated syndromes, and parental awareness of autism spectrum disorder (ASD) children who visited the Medical Research Centre of Excellence, National Research Centre in Cairo, specialized in ASD diagnosis and management. Methods The study included 530 children who were diagnosed with ASD. For those, full medical history, clinical examination, severity evaluation, and testing the language and cognitive development were performed. The process of diagnosis and assessment of parents’ awareness and knowledge about ASD was investigated using questionnaires. Results The clinic was mainly visited by self-referral. About half of the participants (51.4 %) had previously visited other doctors (1–5 physicians) who were mostly pediatricians. The parents’ awareness was mostly limited to the term “autism”, but not the nature of ASD. Caesarean section was the most common risk factor (57.4 %), followed by jaundice (30.1 %). The most common presenting symptoms were language (81.5 %) and social (60.4 %) deficits. ASD severity was found to be high in association with attention deficit hyperactivity disorder (ADHD) and electroencephalogram (EEG) changes (p = 0.001). Conclusion The risk factors and associated syndromes in the Egyptian population studied were similar to those reported in previous studies performed in other populations, but their percentage was different. Perinatal problems were the most common risk factors, which may relate to the influence of gene-environmental interaction on the factors which could play a role in developing ASD or increasing its severity. The process of ASD diagnosis was commonly delayed among the participants. Increasing awareness and knowledge among health care professionals and parents is urgently needed to facilitate early diagnosis and intervention services, which will lead to improvement of the developmental outcomes for ASD children. The associated syndromes could be the driving force to seek medical advice and could influence the ASD severity. En ligne : https://doi.org/10.1016/j.rasd.2021.101781 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=446
in Research in Autism Spectrum Disorders > 84 (June 2021) . - 101781[article] Awareness and risk factors of autism spectrum disorder in an Egyptian population [Texte imprimé et/ou numérique] / Nagwa ABDEL MEGUID, Auteur ; Neveen Hassan NASHAAT, Auteur ; Amal ELSAEID, Auteur ; Massimiliano PEANA, Auteur ; Ahmed ELNAHRY, Auteur ; Geir BJØRKLUND, Auteur . - 101781.
Langues : Anglais (eng)
in Research in Autism Spectrum Disorders > 84 (June 2021) . - 101781
Mots-clés : Autism Awareness Referral situations Risk factors Index. décimale : PER Périodiques Résumé : Background The aim of the present study was to determine the type and percentage of referral situations, risk factors, associated syndromes, and parental awareness of autism spectrum disorder (ASD) children who visited the Medical Research Centre of Excellence, National Research Centre in Cairo, specialized in ASD diagnosis and management. Methods The study included 530 children who were diagnosed with ASD. For those, full medical history, clinical examination, severity evaluation, and testing the language and cognitive development were performed. The process of diagnosis and assessment of parents’ awareness and knowledge about ASD was investigated using questionnaires. Results The clinic was mainly visited by self-referral. About half of the participants (51.4 %) had previously visited other doctors (1–5 physicians) who were mostly pediatricians. The parents’ awareness was mostly limited to the term “autism”, but not the nature of ASD. Caesarean section was the most common risk factor (57.4 %), followed by jaundice (30.1 %). The most common presenting symptoms were language (81.5 %) and social (60.4 %) deficits. ASD severity was found to be high in association with attention deficit hyperactivity disorder (ADHD) and electroencephalogram (EEG) changes (p = 0.001). Conclusion The risk factors and associated syndromes in the Egyptian population studied were similar to those reported in previous studies performed in other populations, but their percentage was different. Perinatal problems were the most common risk factors, which may relate to the influence of gene-environmental interaction on the factors which could play a role in developing ASD or increasing its severity. The process of ASD diagnosis was commonly delayed among the participants. Increasing awareness and knowledge among health care professionals and parents is urgently needed to facilitate early diagnosis and intervention services, which will lead to improvement of the developmental outcomes for ASD children. The associated syndromes could be the driving force to seek medical advice and could influence the ASD severity. En ligne : https://doi.org/10.1016/j.rasd.2021.101781 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=446 Randomized controlled trial of vitamin D supplementation in children with autism spectrum disorder / Khaled SAAD in Journal of Child Psychology and Psychiatry, 59-1 (January 2018)
![]()
[article]
Titre : Randomized controlled trial of vitamin D supplementation in children with autism spectrum disorder Type de document : Texte imprimé et/ou numérique Auteurs : Khaled SAAD, Auteur ; Ahmed A. ABDEL-RAHMAN, Auteur ; Yasser M. ELSEROGY, Auteur ; Abdulrahman A. AL-ATRAM, Auteur ; Amira A. EL-HOUFEY, Auteur ; Hisham A. K. OTHMAN, Auteur ; Geir BJØRKLUND, Auteur ; Feiyong JIA, Auteur ; Mauricio A. URBINA, Auteur ; Mohamed Gamil M. ABO-ELELA, Auteur ; Faisal-Alkhateeb AHMAD, Auteur ; Khaled A. ABD EL-BASEER, Auteur ; Ahmed E. AHMED, Auteur ; Ahmad M. ABDEL-SALAM, Auteur Article en page(s) : p.20-29 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder vitamin D children clinical trial Index. décimale : PER Périodiques Résumé : Background Autism spectrum disorder (ASD) is a frequent developmental disorder characterized by pervasive deficits in social interaction, impairment in verbal and nonverbal communication, and stereotyped patterns of interests and activities. It has been previously reported that there is vitamin D deficiency in autistic children; however, there is a lack of randomized controlled trials of vitamin D supplementation in ASD children. Methods This study is a double-blinded, randomized clinical trial (RCT) that was conducted on 109 children with ASD (85 boys and 24 girls; aged 3–10 years). The aim of this study was to assess the effects of vitamin D supplementation on the core symptoms of autism in children. ASD patients were randomized to receive vitamin D3 or placebo for 4 months. The serum levels of 25-hydroxycholecalciferol (25 (OH)D) were measured at the beginning and at the end of the study. The autism severity and social maturity of the children were assessed by the Childhood Autism Rating Scale (CARS), Aberrant Behavior Checklist (ABC), Social Responsiveness Scale (SRS), and the Autism Treatment Evaluation Checklist (ATEC). Trial registration number: UMIN-CTR Study Design: trial number: UMIN000020281. Results Supplementation of vitamin D was well tolerated by the ASD children. The daily doses used in the therapy group was 300 IU vitamin D3/kg/day, not to exceed 5,000 IU/day. The autism symptoms of the children improved significantly, following 4-month vitamin D3 supplementation, but not in the placebo group. This study demonstrates the efficacy and tolerability of high doses of vitamin D3 in children with ASD. Conclusions This study is the first double-blinded RCT proving the efficacy of vitamin D3 in ASD patients. Depending on the parameters measured in the study, oral vitamin D supplementation may safely improve signs and symptoms of ASD and could be recommended for children with ASD. At this stage, this study is a single RCT with a small number of patients, and a great deal of additional wide-scale studies are needed to critically validate the efficacy of vitamin D in ASD. En ligne : http://dx.doi.org/10.1111/jcpp.12652 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=327
in Journal of Child Psychology and Psychiatry > 59-1 (January 2018) . - p.20-29[article] Randomized controlled trial of vitamin D supplementation in children with autism spectrum disorder [Texte imprimé et/ou numérique] / Khaled SAAD, Auteur ; Ahmed A. ABDEL-RAHMAN, Auteur ; Yasser M. ELSEROGY, Auteur ; Abdulrahman A. AL-ATRAM, Auteur ; Amira A. EL-HOUFEY, Auteur ; Hisham A. K. OTHMAN, Auteur ; Geir BJØRKLUND, Auteur ; Feiyong JIA, Auteur ; Mauricio A. URBINA, Auteur ; Mohamed Gamil M. ABO-ELELA, Auteur ; Faisal-Alkhateeb AHMAD, Auteur ; Khaled A. ABD EL-BASEER, Auteur ; Ahmed E. AHMED, Auteur ; Ahmad M. ABDEL-SALAM, Auteur . - p.20-29.
Langues : Anglais (eng)
in Journal of Child Psychology and Psychiatry > 59-1 (January 2018) . - p.20-29
Mots-clés : Autism spectrum disorder vitamin D children clinical trial Index. décimale : PER Périodiques Résumé : Background Autism spectrum disorder (ASD) is a frequent developmental disorder characterized by pervasive deficits in social interaction, impairment in verbal and nonverbal communication, and stereotyped patterns of interests and activities. It has been previously reported that there is vitamin D deficiency in autistic children; however, there is a lack of randomized controlled trials of vitamin D supplementation in ASD children. Methods This study is a double-blinded, randomized clinical trial (RCT) that was conducted on 109 children with ASD (85 boys and 24 girls; aged 3–10 years). The aim of this study was to assess the effects of vitamin D supplementation on the core symptoms of autism in children. ASD patients were randomized to receive vitamin D3 or placebo for 4 months. The serum levels of 25-hydroxycholecalciferol (25 (OH)D) were measured at the beginning and at the end of the study. The autism severity and social maturity of the children were assessed by the Childhood Autism Rating Scale (CARS), Aberrant Behavior Checklist (ABC), Social Responsiveness Scale (SRS), and the Autism Treatment Evaluation Checklist (ATEC). Trial registration number: UMIN-CTR Study Design: trial number: UMIN000020281. Results Supplementation of vitamin D was well tolerated by the ASD children. The daily doses used in the therapy group was 300 IU vitamin D3/kg/day, not to exceed 5,000 IU/day. The autism symptoms of the children improved significantly, following 4-month vitamin D3 supplementation, but not in the placebo group. This study demonstrates the efficacy and tolerability of high doses of vitamin D3 in children with ASD. Conclusions This study is the first double-blinded RCT proving the efficacy of vitamin D3 in ASD patients. Depending on the parameters measured in the study, oral vitamin D supplementation may safely improve signs and symptoms of ASD and could be recommended for children with ASD. At this stage, this study is a single RCT with a small number of patients, and a great deal of additional wide-scale studies are needed to critically validate the efficacy of vitamin D in ASD. En ligne : http://dx.doi.org/10.1111/jcpp.12652 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=327